A Phase 1, Randomized, Open-Label, Single-Center, Single-Dose, Two-Period Two-Part Crossover Study in Healthy Subjects to Compare the Bioavailability of Dexlansoprazole From Dexlansoprazole Delayed-Release Capsules 30 mg and 60 mg Manufactured by Takeda GmbH Plant Oranienburg Relative to Dexlansoprazole Delayed-Release Capsules 30 mg and 60 mg Manufactured by Takeda Pharmaceutical Company Limited Osaka Plant
Latest Information Update: 17 Jun 2019
At a glance
- Drugs Dexlansoprazole (Primary)
- Indications Erosive oesophagitis; Gastro-oesophageal reflux; Gastrointestinal disorders
- Focus Pharmacokinetics
- Sponsors Takeda
- 28 Jul 2017 Status changed from recruiting to completed.
- 03 May 2017 New trial record